On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
ThursdayAug 22, 2019 10:41 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Commercial Launch of ChrgD+

Biotechnology company and global drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced the commercial launch of ChrgD+, the industry’s most advanced water-soluble multi-spectrum hemp oil in a powdered format and empowered with DehydraTECH(TM) for fast, effective delivery. ChrgD+ is available online, now for sale to US consumers at ChrgD.life. Lexaria’s technology delivers patented processes within every ChrgD+ serving to improve the consumer experience of hemp oil with CBD. ChrgD+ is formulated with the highest quality multi-spectrum hemp oil ingredients and does NOT use CBD isolates that deprive consumers of the synergistic benefits of multi-spectrum oils. In…

Continue Reading

TuesdayAug 20, 2019 2:30 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Joint Manufacturing Partnership Opens Door to Widespread Distribution

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a biotechnology company and drug-delivery platform innovator, is increasing the reach of its revolutionary DehydraTECH(TM) technology that enables the rapid onset of ingested cannabis. An article discussing the company reads, “DehydraTECH is a drug-delivery technology that gets ingested active pharmaceutical ingredient (API) molecules to the bloodstream faster than other methods. Under a new agreement announced July 24, the company will expand DehydraTECH’s reach by allowing Hill Street Beverage Company Inc. (TSX.V: BEER), a manufacturer of alcohol-free and cannabis-infused beer, wine and adult-format beverages, to produce commercial products in partnership with Lexaria under a new…

Continue Reading

TuesdayAug 20, 2019 11:38 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Drug-Delivery Platform Could Help Smokers Stub Cigarettes

Lexaria recently announced its entry into a partnership with a tobacco giant to fund the research and development of oral nicotine delivery solutions The company received a cannabis R&D license from Health Canada LXRP also announced its receipt of four new patents and its launch of ChrgD+ Many consumers don’t realize that they don’t need to smoke to partake of nicotine. In fact, new advancements are providing an alternative to the risks associated with smoking, which were first officially revealed by a damning surgeon general report in 1963 linking smoking to lung cancer, emphysema and heart disease. Case in point,…

Continue Reading

MondayAug 19, 2019 1:05 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) R&D Finds Lack of Adverse Chemical Byproducts in Manufacture of Drug Delivery Compositions

Lexaria Bioscience is involved in the research and improvement of its trademarked DehydraTECH technology, which enhances the bioavailability of some legal drug substances used by consumers The technology provides a rapid-on, rapid-off effect that may be effectively used in cannabis-infused edibles and beverages as an alternative to mind-altering substances such as alcohol and cannabis New research has boosted Lexaria’s hopes, with findings that show no adverse NME chemical compositions were formed in several rounds of in-depth testing The company recently formed a collaboration with Hill Street Beverage Company to make cannabis-infused alternatives to alcoholic beverages By 2024, cannabis-infused beverage sales…

Continue Reading

ThursdayAug 15, 2019 10:15 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Receives Four New Patents, Increasing Total Granted to 15

Biotechnology company and global drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced the granting of four of its pending patent applications via its wholly-owned subsidiary Poviva Corp. According to the update, the new patents cover delivery of cannabinoids such as THC and CBD, NSAIDs such as ibuprofen, nicotine, and vitamins. With issuance of these four patents, Lexaria’s total patents granted has increased to 15, with eight in the US and seven in Australia, and the company has roughly 60 patent applications pending throughout the world. Lexaria is one of the most patent-rich firms in the Western…

Continue Reading

WednesdayAug 14, 2019 12:43 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Appoints Consumer Packaged Goods Veteran to Board of Directors

Biotechnology company and global drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced the appointment of Brian Quigley to its board of directors. Quigley most recently spent 16 years at Altria Group, seven of which were spent as president and CEO for U.S. Smokeless Tobacco and Nu-Mark, Altria's innovation company, during the time that the existing Lexaria and Altria business relationship was negotiated. Quigley is a 20-year Consumer Packaged Goods veteran with a background of managing complex regulatory environments including for novel and innovative nicotine products, and holds additional deep experience with operations and marketing. “Lexaria continues…

Continue Reading

TuesdayAug 13, 2019 9:49 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) Subsidiary Receives Health Canada Cannabis R&D License

Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) today announced that Health Canada has issued cannabis Research and Development (“R&D”) license LIC-7NONT76UNW-2019 to its subsidiary, Lexaria CanPharm ULC. According to the update, the license, which carries a four-year term unless renewed, is effective immediately and will allow one of the country’s newest and most advanced formulation laboratories to conduct extensive investigatory work in THC and CBD delivery using optimized, proprietary formulations and techniques. The purpose-built laboratory is permitted at local and federal levels and fully outfitted to produce DehydraTECH(TM) infusions and includes two different…

Continue Reading

ThursdayAug 08, 2019 10:07 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Completes Initial R&D Program with the National Research Council of Canada

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced successful completion of its Master Collaborative Research Agreement (“the R&D Program”) with the National Research Council of Canada (“NRC”). The R&D program sought to investigate technical aspects and new opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions using Lexaria’s patented DehydraTECH(TM) technology with a primary goal to determine whether, through its processing, DehydraTECH causes the formation of a new molecular entity (“NME”). According to the update, all evidence aligns to confirm that no covalent-bonded NME is created with Lexaria’s technology. Processes or technologies…

Continue Reading

TuesdayAug 06, 2019 11:18 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reviews Expansion of Client Base, Noting Unprecedented Number of License Agreements

Lexaria’s patented DehydraTECH technology improves taste, achieves higher absorption rates and promotes fast onset of bioactive compounds, including nicotine and cannabinoids Nine corporate licensees have signed a total of 11 definitive contracts to use DehydraTECH technology in innovative beverages, edibles and oral products Lexaria expects to experience unprecedented revenue growth as many of its clients plan aggressive rollouts and growth for their product lines Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is expanding its family of existing licensees and partners with an impressive lineup of new corporate licensees for use of Lexaria’s patented DehydraTECH…

Continue Reading

MondayAug 05, 2019 12:02 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Paves Way for New Cannabis Brand, B2B Sales through Partnership with Alcohol-Free Beverage Maker

Lexaria Bioscience’s revolutionary DehydraTECH technology enables cannabis consumers to experience rapid-on, rapid-off effects in non-smoked formulations A just-announced joint manufacturing partnership between Lexaria and alcohol-free beverage maker Hill Street Beverage Company is paving the way for wider distribution of Lexaria’s platform Hill Street is the only company to have gained licenses to use DehydraTECH on a global basis, taking advantage of Lexaria’s multiple international granted and pending patents By 2024, cannabis-infused beverage sales are expected to rise by nearly 15 times from last year’s revenues of $89 million The exploding interest in cannabis products and in new ways of enjoying…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.


Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered